Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
about
Cancer Stem Cell Plasticity Drives Therapeutic ResistanceCancer stem cell targeted therapy: progress amid controversies.A role for G-CSF and GM-CSF in nonmyeloid cancersPLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cellsSTAT3 and epithelial-mesenchymal transitions in carcinomasHiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression.Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasisCharacterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancerBlockage of TGFβ-SMAD2 by demethylation-activated miR-148a is involved in caffeic acid-induced inhibition of cancer stem cell-like properties in vitro and in vivo.Microenvironment and endocrine resistance in breast cancer: Friend or foe?G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancerRole of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells.Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.Oncostatin M stimulates cell migration and proliferation by down-regulating E-cadherin in HTR8/SVneo cell line through STAT3 activation.The enigmatic cytokine oncostatin m and roles in diseaseIntegrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.MicroRNA profiling of CD3+ CD56+ cytokine-induced killer cells.Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer.Role of STAT3 pathway in genitourinary tumors.STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.Mitogen-activated protein kinase signaling controls basal and oncostatin M-mediated JUNB gene expression.Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.Fentanyl Promotes Breast Cancer Cell Stemness and Epithelial-Mesenchymal Transition by Upregulating α1, 6-Fucosylation via Wnt/β-Catenin Signaling Pathway.Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.Salinomycin kills cancer stem cells by sequestering iron in lysosomes.OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.
P2860
Q26770274-68A4F971-85E3-49D4-8B3D-0FBBE00900AEQ26779931-56F1FA17-9F05-49B3-A8E9-0379CCBD4323Q27002515-CF3D9CC8-4084-46B3-AF77-D0CCFDEA2CA2Q33593900-703BF2A3-9E53-4E21-A3BC-29E894E5748EQ33623947-60EB1CAF-2DE5-448B-AE1E-D0D36206E323Q33820241-D166C449-87EC-4B23-AF18-7143F73BBB01Q33902576-EACF6951-5BBE-46FC-9D12-B2AE74A1E7F9Q34658788-92C4B3B8-2079-4C1F-8013-779A2F4C4567Q35084743-490E8626-9C7A-4655-80CF-4458A3311F5CQ35182981-8B6DA88D-C0AD-4523-A342-DAE1273C6010Q35763804-216890F2-4078-4E53-9EDA-A540B96EEB9CQ36363626-7D77A751-D67C-4409-958E-94A841C211A8Q36821159-8BB24364-9CA1-40D8-8FE7-796C18AB5422Q37007247-F9C9DC6D-41E9-443B-B32A-151B12FBA571Q37100743-981F15A5-EBA2-4B00-AD48-46441FF933DCQ37361317-49B38585-2BA1-48CC-95DE-8EE7E95DCC8BQ37409222-AD6DCD06-02AD-453D-B14D-6F647537D508Q37631676-CD2AC638-6DF0-4095-853A-4FF000F76B8EQ37737350-B0FB89BF-28AA-40DD-8E40-32844EC520B8Q38369000-93BAD145-D3E5-4AA0-A306-7ABB682B9FC3Q38669181-0D4841F0-882F-4297-8331-92C0F2BDAA41Q38776978-8D9C74AF-EDA4-476F-BC35-2465ACD6CC3CQ38790057-095670A6-B222-4E67-ADEF-FDB737B15B5BQ38911668-650312E6-408A-4355-9E8F-825209114C95Q39039925-66EC4236-5DD4-4391-B50D-3008321FF904Q39407129-B27153DA-504E-4528-8897-911D322BB578Q41124448-23985039-263C-45D1-9361-603B6710EFDCQ41846031-303F4406-D781-42A8-B545-46FDFD912EC0Q42094834-CC4C1FF8-61AB-4F8E-8054-9A61DE179C49Q46302821-C989FAC9-A046-4887-8233-1D3AA0F19E7AQ55413893-CF443331-7ADD-485B-98D3-D4496D4CD5D8
P2860
Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Oncostatin-M promotes phenotyp ...... ferentiation in breast cancer.
@en
Oncostatin-M promotes phenotyp ...... ferentiation in breast cancer.
@nl
type
label
Oncostatin-M promotes phenotyp ...... ferentiation in breast cancer.
@en
Oncostatin-M promotes phenotyp ...... ferentiation in breast cancer.
@nl
prefLabel
Oncostatin-M promotes phenotyp ...... ferentiation in breast cancer.
@en
Oncostatin-M promotes phenotyp ...... ferentiation in breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Oncostatin-M promotes phenotyp ...... ferentiation in breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2013.105
P407
P577
2013-04-15T00:00:00Z
P6179
1013092045